Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -28.22% is in line with its 5-year average of -26.24%, around the middle of its 5-year range (-35.20%–-16.55%).
4.92% above its 12-month average of -29.68%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.58%.
RETURN ON ASSETS (ROA)
-28.22%
RETURN ON ASSETS (ROA) AVG TTM
-29.68%
RETURN ON ASSETS (ROA) AVG 3Y
-31.08%
RETURN ON ASSETS (ROA) AVG 5Y
-26.24%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.92%
CURRENT VS 3Y AVG
+9.19%
CURRENT VS 5Y AVG
-7.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.14%
median of 570 covered companies
CURRENT VS SECTOR MEDIAN
-0.27%
vs the sector median at left
C4 Therapeutics, Inc.
Market Cap
$324.51M
Return on Assets (ROA)
-28.22%
TTM Avg
-29.68%
3Y Avg
-31.08%
5Y Avg
-26.24%
Market Cap
$323.01M
Return on Assets (ROA)
-160.64%
TTM Avg
-128.90%
3Y Avg
-103.44%
5Y Avg
-103.44%
Market Cap
$321.22M
Return on Assets (ROA)
-70.63%
TTM Avg
-82.15%
3Y Avg
-59.06%
5Y Avg
-50.33%
Market Cap
$313.54M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
Market Cap
$336.78M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$340.84M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$341.87M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$306.52M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$305.75M
Return on Assets (ROA)
-24.94%
TTM Avg
-31.51%
3Y Avg
-135.72%
5Y Avg
-152.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $324.51M | -28.22% | -29.68% | -31.08% | -26.24% |
| CapsoVision, Inc. (CV)vs › | $323.01M | -160.64% | -128.90% | -103.44% | -103.44% |
| Cabaletta Bio, Inc. (CABA)vs › | $321.22M | -70.63% | -82.15% | -59.06% | -50.33% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $313.54M | -96.57% | -96.57% | -96.57% | -96.57% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $336.78M | -39.85% | -37.20% | -38.95% | -33.46% |
| Agenus Inc. (AGEN)vs › | $340.84M | 53.28% | -50.19% | -57.97% | -53.56% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.87M | -24.64% | -45.98% | -40.55% | -44.33% |
| Standard BioTools Inc. (LAB)vs › | $306.52M | -13.93% | -17.93% | -26.92% | -24.25% |
| Benitec Biopharma Inc. (BNTC)vs › | $305.75M | -24.94% | -31.51% | -135.72% | -152.11% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.69M | -21.30% | -29.99% | -30.23% | -24.37% |
ROA
-28.2%
ROE
-41.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -29.24% |
| 2024-12-31 | -30.12% |
| 2023-12-31 | -35.20% |
| 2022-12-31 | -29.75% |
| 2021-12-31 | -16.55% |
| 2020-12-31 | -16.58% |
| 2019-12-31 | -28.83% |
| 2018-12-31 | -10.72% |
